[dropcap]O[/dropcap]ur endorsement in August 2017 proved to be an ideal entry point for Vifor Pharma – the small-cap play has been the ace performer in…
[dropcap]B[/dropcap]anks have over-performed the market over the past two years, recovering a portion of the ground lost during the first half of 2016 on overdone…
[dropcap]T[/dropcap]he asset management (and asset gathering as a whole including the Life insurance business) has been reshuffling at an exponential speed over the last few…
[dropcap]W[/dropcap]e believe concerns about the potential impacts of accelerated digital investments on dividends are misplaced. In our view, they are based on a misconception of…
When AXA presented two years ago its “Ambition 2020” plan, it was considered as rather ambitious indeed, and, when a refreshed management team took the helm,…
[dropcap]T[/dropcap]he taste for dividends is largely a reflection on the (shifting) taste for risk but their quality as a safety-net cannot be challenged. Consider the…
The primarily domestic Swiss telco has been a remarkable performer whatever investors sentiment about the CHF, about Swiss growth, about Telcos at large and about…
Novartis reported yet another strong quarter, reflecting strong performance by Cosentyx, Entresto and Alcon, although Sandoz remains a worry. The guidance reiterates the same mood…
[dropcap]U[/dropcap]tilities have lost their shine since October 2017. This can easily be associated with firmer rates and a dash for cyclical/value stocks now that Europe…